ClinicalTrials.gg
TerminatedNCT04999020Updated Jul 9, 2025Results posted

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

A Phase 2/3 interventional study of Ravulizumab and Placebo in Dermatomyositis, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 111 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.

Enrollment
31st of 73
38 · median 25
Started
2021
with 3 others
Phase 2/3
8 of 94
2 open now
Registered
56th of 94
by date

Among the 94 studies in Dermatomyositis with a site in United States, this one is the 31st largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2021, is one of 8 in phase 2/3, and was the 56th registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Dermatomyositis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

Read the detailed description

The study will be conducted in 2 parts: Part A (Phase 2) and Part B (Phase 3). There will be 3 periods in both Part A and Part B of this study: Screening Period, Randomized Controlled Period, and Open-Label Extension Period.

03

Conditions studied

  • Dermatomyositis

Browse trials for

Keywords

  • Ravulizumab
  • ALXN1210
  • Ultomiris
  • Pharmacokinetics
  • Pharmacodynamics
  • Efficacy
  • DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 years of age or older at the time of signing the .
  • Body weight ≥ 30 kilograms at the time of Screening.
  • Male or female.
  • Diagnosis: Meet 2017 American College of Rheumatology/European League Against Rheumatism classification criteria for definite or probable DM.
  • Participants who have an inadequate response or are intolerant to 1 or more DM treatments, including systemic or /immunomodulatory therapies (for example, azathioprine, methotrexate, rituximab, intravenous immunoglobulin), either in combination or as monotherapy.
  • Vaccinated against Neisseria meningitidis within 3 years prior to initiating ravulizumab as per national and local guidelines. Participants must receive the vaccination at least 2 weeks before first study intervention. The sponsor recommends that national and local guidelines for prophylactic antibiotics should also be followed.
  • Female participants of and male participants must follow specified guidance as described in the protocol.

Key Exclusion Criteria:

  • Participants who have been diagnosed with cancer within the last 3 years need to have appropriate negative cancer screening as per local standard of care within 6 months before Screening (basal or squamous cell skin cancer or carcinoma in situ of the cervix needs to have been excised and without evidence of residual disease for at least 3 months before Screening).
  • Evidence of active malignant disease or diagnosed within the previous 3 years including hematological malignancies and solid tumors.
  • Participants with other forms of myositis.
  • As per investigator discretion, participants with significant muscle damage (for example, severe muscle atrophy, end stage muscle disease, MRI with severe atrophy or fibrofatty replacement)
  • History of Neisseria meningitidis infection.
  • (HIV) infection (evidenced by HIV Type 1 or Type 2 antibody titer).
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to ravulizumab administration.
  • Presence of fever ≥ 38°Celsius (100.4°Fahrenheit) within 7 days prior to study drug administration on Day 1.
  • History of to murine proteins or to 1 of the of ravulizumab.
  • Pregnant, breastfeeding, or intending to conceive during the course of the study.
  • Inability or unwillingness to adhere to the protocol requirements.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    Participants will receive ravulizumab in both Parts A and B.

    Drug: Ravulizumab

  • Placebo comparator
    Placebo

    Participants will receive placebo in both Parts A and B.

    Drug: Placebo

Interventions

  • Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.

    Also known as: ALXN1210, Ultomiris

  • DrugPlacebo

    Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period

    Data are presented for the number of participants with a TIS40 response, defined as an IMACS-TIS score ≥ 40 at Week 26. IMACS-TIS is a clinical instrument that encompasses 6 core set measure (CSMs) (physician, patient, extra-muscular global activity, muscle strength, Health Assessment Questionnaire \[HAQ\], and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. A higher score indicated greater improvement. TIS40 was considered a moderate improvement score.

    Time frame: Week 26

Secondary outcomes

  1. TIS at Week 26

    TIS scores ranged from 0-100 with higher scores indicating a greater improvement. Scores were determined by summing scores in each of the 6 CSMs of the IMAC (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). Clinically meaningful thresholds for improvement were defined as ≥ 20 point improvement response on IMACS-TIS (TIS20; mild), ≥ 40 point improvement response on IMACS TIS (TIS40; moderate) and ≥ 60 point improvement response on IMACS-TIS (TIS60; severe). Scores were based on the improvement and relative weight of each CSM. Data are presented for TIS (least squares mean) at Week 26.

    Time frame: Week 26

  2. Change From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26

    The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Change from baseline in CDASI Total Activity Score at Week 26 was analyzed using a mixed model repeated measures (MMRM). The MMRM model included the observed Total Activity Score values at post baseline visits (Week 26) as the dependent variable.

    Time frame: Baseline, Week 26

  3. Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26

    Laboratory tests were conducted to measure serum activities of muscle associated enzymes including creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and aldolase. Data are presented for the number of participants who had an abnormal muscle enzyme at baseline that had been normalized at Week 26.

    Time frame: Baseline, Week 26

  4. Change From Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26

    The MDAAT assesses disease activity of extra-muscular organ systems and muscles in participants with DM. The validated MDAAT tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0-10 centimeter (cm) visual analog scale (VAS). Extra-muscular activity ranged between 0 and 10, where, 0 cm = absent and 10 cm = maximum disease activity.

    Time frame: Baseline, Week 26

  5. Change From Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26

    The physician global activity assessment provides an overall rating of disease activity related to myositis. Disease activity is judged by the physician based on all information available at the time of evaluation, including the participant's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. The global disease activity score is recorded on a 10-cm VAS, where 0 cm= no evidence of disease activity and 10 cm= extremely severe disease activity.

    Time frame: Baseline, Week 26

  6. Change From Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26

    The patient global activity assessment provides an overall rating of disease activity related to myositis from the participant's perspective. Participants were asked to consider all of the active inflammation in their own muscles, skin, joints, intestines, heart, lungs, or other parts of the body that can improve with treatment. The patient global disease activity score was recorded on a 10-cm VAS that contained a smiley face at the 0-cm anchor and a sad face at the 10 cm anchor to help participants understand the scale. Scores ranged from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity).

    Time frame: Baseline, Week 26

  7. Change From Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26

    The purpose of the MMT-8 was to measure muscle strength as part of the physical examination. It included a subset of 8 muscle groups: neck flexors, deltoids, biceps, wrist, extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors. Total MMT8 scores ranged from 0 (lowest strength) to 150 (highest strength).

    Time frame: Baseline, Week 26

  8. Change From Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26

    The HAQ is a brief self-report questionnaire that assesses physical function pertaining to activities of daily living in a variety of domains. The HAQ includes 20 questions relating to 8 domains of function: dressing and grooming, arising, eating, walking, hygiene, reach, grip and usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability.

    Time frame: Baseline, Week 26

  9. Number of Participants With CDASI Response (>=7-point Improvement) at Week 26

    The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Data are presented for the number of participants with a CDASI response. Response was defined as a \>=7 point improvement in participants who did not have an intercurrent event at or prior to the relevant timepoint.

    Time frame: Week 26

  10. Number of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26

    CDA-IGA is a scale that was created to measure disease severity in participants with skin disease. It is a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) with morphologic descriptors for each score. The CDA-IGA was completed by the Investigator and was used to describe the overall appearance of lesions at a given time point. Data are presented for the number of participants with a CDA-IGA response at Week 26. A response was defined as participants with clear or almost clear skin (score of 0 or 1) who did not have an intercurrent event at or before the relevant timepoint.

    Time frame: Week 26

  11. Number of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26

    TIS20 was defined as a ≥20-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20 is considered a mild improvement score.

    Time frame: Week 26

  12. Number of Participants With ≥ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26

    TIS60 was defined as a ≥60-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS60 is considered a severe improvement score.

    Time frame: Week 26

  13. Time to First Response of TIS20, TIS40, or TIS60

    TIS20, 40 and 60 were defined as a ≥20, ≥40 and ≥60-point improvement response on IMACS-TIS respectively. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, and extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20, 40 and 60 were considered mild, moderate and severe improvement scores respectively. Data are presented for the time to first response of TIS20, TIS40, or TIS60. The median time to TIS20, TIS40, and TIS60 was defined at the time in which 50% of the participants experienced TIS20, TIS40, or TIS60, respectively, based on a Kaplan-Meier analysis.

    Time frame: Baseline through Week 26

  14. Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits

    CW was defined as one of the following: 1. Physician's global activity VAS worsening ≥ 2 cm and MMT-8 worsening ≥ 20% compared to baseline 2. Global extra muscular activity worsening ≥ 2 cm on the MDAAT VAS compared to baseline 3. Any 3 of 5 CSMs (excluding muscle enzymes) worsening by ≥ 30% compared to baseline Data are presented for the number of participants with clinical worsening during the RCP at 2 consecutive visits.

    Time frame: Baseline through Week 26

  15. Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment

    Acute rescue therapy with standard DM treatment included an increased dose of a medication that was being taken for DM or the initiation of a new DM treatment (glucocorticoid and/or immunosuppressive/immunomodulatory therapy \[ISTs\]). Data are presented for the number of participants who received acute rescue therapy with standard DM treatment.

    Time frame: Baseline through Week 26

07

Results

Posted Dec 6, 2024
Limitations and caveats
Part A did not meet its primary endpoint and the study was terminated.

Participant flow

Randomized Controlled Period (RCP)
Participant flow — Randomized Controlled Period (RCP)
MilestoneRCP: RavulizumabRCP: PlaceboOLE: Ravulizumab to RavulizumabOLE: Placebo to Ravulizumab
Started261200
Received at least 1 dose of treatment261200
Completed22900
Not completed4300
Withdrew: Withdrawal by subject1200
Withdrew: Physician decision1100
Withdrew: Adverse event2000
Open-Label Extension (OLE) Period
Participant flow — Open-Label Extension (OLE) Period
MilestoneRCP: RavulizumabRCP: PlaceboOLE: Ravulizumab to RavulizumabOLE: Placebo to Ravulizumab
Started00229
Received at least 1 dose of treatment00229
Completed0000
Not completed00229
Withdrew: Withdrawal by subject0033
Withdrew: Study terminated by sponsor00174
Withdrew: Physician decision0010
Withdrew: Lost to follow-up0010
Withdrew: Adverse event0002

Outcome measures

PrimaryNumber of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period

Data are presented for the number of participants with a TIS40 response, defined as an IMACS-TIS score ≥ 40 at Week 26. IMACS-TIS is a clinical instrument that encompasses 6 core set measure (CSMs) (physician, patient, extra-muscular global activity, muscle strength, Health Assessment Questionnaire \[HAQ\], and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. A higher score indicated greater improvement. TIS40 was considered a moderate improvement score.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period96
Statistical analysis
  • RCP: Ravulizumab vs RCP: Placebo · Barnard's unconditional exact test · p = 0.4192 · Difference in response rates: -15.38 · 80% CI -38.55 to 8.48
SecondaryTIS at Week 26

TIS scores ranged from 0-100 with higher scores indicating a greater improvement. Scores were determined by summing scores in each of the 6 CSMs of the IMAC (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). Clinically meaningful thresholds for improvement were defined as ≥ 20 point improvement response on IMACS-TIS (TIS20; mild), ≥ 40 point improvement response on IMACS TIS (TIS40; moderate) and ≥ 60 point improvement response on IMACS-TIS (TIS60; severe). Scores were based on the improvement and relative weight of each CSM. Data are presented for TIS (least squares mean) at Week 26.

Time frame:
Week 26
Reported as:
Least squares mean · scores on a scale
TIS at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
TIS at Week 2631.16 ± 4.18543.28 ± 6.650
SecondaryChange From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26

The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Change from baseline in CDASI Total Activity Score at Week 26 was analyzed using a mixed model repeated measures (MMRM). The MMRM model included the observed Total Activity Score values at post baseline visits (Week 26) as the dependent variable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26-3.80 ± 1.249-7.47 ± 2.021
SecondaryNumber of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26

Laboratory tests were conducted to measure serum activities of muscle associated enzymes including creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and aldolase. Data are presented for the number of participants who had an abnormal muscle enzyme at baseline that had been normalized at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 2641
SecondaryChange From Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26

The MDAAT assesses disease activity of extra-muscular organ systems and muscles in participants with DM. The validated MDAAT tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0-10 centimeter (cm) visual analog scale (VAS). Extra-muscular activity ranged between 0 and 10, where, 0 cm = absent and 10 cm = maximum disease activity.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26-0.92 ± 0.383-2.13 ± 0.614
SecondaryChange From Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26

The physician global activity assessment provides an overall rating of disease activity related to myositis. Disease activity is judged by the physician based on all information available at the time of evaluation, including the participant's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. The global disease activity score is recorded on a 10-cm VAS, where 0 cm= no evidence of disease activity and 10 cm= extremely severe disease activity.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26-1.18 ± 0.413-1.97 ± 0.649
SecondaryChange From Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26

The patient global activity assessment provides an overall rating of disease activity related to myositis from the participant's perspective. Participants were asked to consider all of the active inflammation in their own muscles, skin, joints, intestines, heart, lungs, or other parts of the body that can improve with treatment. The patient global disease activity score was recorded on a 10-cm VAS that contained a smiley face at the 0-cm anchor and a sad face at the 10 cm anchor to help participants understand the scale. Scores ranged from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26-1.43 ± 0.432-1.12 ± 0.699
SecondaryChange From Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26

The purpose of the MMT-8 was to measure muscle strength as part of the physical examination. It included a subset of 8 muscle groups: neck flexors, deltoids, biceps, wrist, extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors. Total MMT8 scores ranged from 0 (lowest strength) to 150 (highest strength).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 269.5 ± 1.8512.6 ± 2.98
SecondaryChange From Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26

The HAQ is a brief self-report questionnaire that assesses physical function pertaining to activities of daily living in a variety of domains. The HAQ includes 20 questions relating to 8 domains of function: dressing and grooming, arising, eating, walking, hygiene, reach, grip and usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26
scores on a scaleRCP: RavulizumabRCP: Placebo
Change From Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26-0.1289 ± 0.08607-0.4188 ± 0.13676
SecondaryNumber of Participants With CDASI Response (>=7-point Improvement) at Week 26

The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Data are presented for the number of participants with a CDASI response. Response was defined as a \>=7 point improvement in participants who did not have an intercurrent event at or prior to the relevant timepoint.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With CDASI Response (>=7-point Improvement) at Week 26
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With CDASI Response (>=7-point Improvement) at Week 2664
SecondaryNumber of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26

CDA-IGA is a scale that was created to measure disease severity in participants with skin disease. It is a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) with morphologic descriptors for each score. The CDA-IGA was completed by the Investigator and was used to describe the overall appearance of lesions at a given time point. Data are presented for the number of participants with a CDA-IGA response at Week 26. A response was defined as participants with clear or almost clear skin (score of 0 or 1) who did not have an intercurrent event at or before the relevant timepoint.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 2652
SecondaryNumber of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26

TIS20 was defined as a ≥20-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20 is considered a mild improvement score.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26149
SecondaryNumber of Participants With ≥ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26

TIS60 was defined as a ≥60-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS60 is considered a severe improvement score.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With ≥ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With ≥ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 2632
SecondaryTime to First Response of TIS20, TIS40, or TIS60

TIS20, 40 and 60 were defined as a ≥20, ≥40 and ≥60-point improvement response on IMACS-TIS respectively. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, and extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20, 40 and 60 were considered mild, moderate and severe improvement scores respectively. Data are presented for the time to first response of TIS20, TIS40, or TIS60. The median time to TIS20, TIS40, and TIS60 was defined at the time in which 50% of the participants experienced TIS20, TIS40, or TIS60, respectively, based on a Kaplan-Meier analysis.

Time frame:
Baseline through Week 26
Reported as:
Median · weeks
Time to First Response of TIS20, TIS40, or TIS60
weeksRCP: RavulizumabRCP: Placebo
Time to TIS2010.43 (10.14 to 17.86)10.14 (2.14 to 10.14)
Time to TIS4025.86 (18.14 to NA)26.0 (10.14 to 26.29)
Time to TIS60NA (NA to NA)NA (26.14 to NA)
SecondaryNumber of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits

CW was defined as one of the following: 1. Physician's global activity VAS worsening ≥ 2 cm and MMT-8 worsening ≥ 20% compared to baseline 2. Global extra muscular activity worsening ≥ 2 cm on the MDAAT VAS compared to baseline 3. Any 3 of 5 CSMs (excluding muscle enzymes) worsening by ≥ 30% compared to baseline Data are presented for the number of participants with clinical worsening during the RCP at 2 consecutive visits.

Time frame:
Baseline through Week 26
Reported as:
Count of participants · Participants
Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits20
SecondaryNumber of Participants Who Received Acute Rescue Therapy With Standard DM Treatment

Acute rescue therapy with standard DM treatment included an increased dose of a medication that was being taken for DM or the initiation of a new DM treatment (glucocorticoid and/or immunosuppressive/immunomodulatory therapy \[ISTs\]). Data are presented for the number of participants who received acute rescue therapy with standard DM treatment.

Time frame:
Baseline through Week 26
Reported as:
Count of participants · Participants
Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment
ParticipantsRCP: RavulizumabRCP: Placebo
Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment20

Adverse events

Collected over Up to approximately 130 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RCP: Ravulizumab0/25 (0%)2/25 (8%)9/25 (36%)
RCP: Placebo0/13 (0%)0/13 (0%)10/13 (76.9%)
OLE: Ravulizumab to Ravulizumab0/22 (0%)4/22 (18.2%)11/22 (50%)
OLE: Placebo to Ravulizumab0/9 (0%)4/9 (44.4%)7/9 (77.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRCP: RavulizumabRCP: PlaceboOLE: Ravulizumab to RavulizumabOLE: Placebo to Ravulizumab
AnaemiaBlood and lymphatic system disorders0/250/130/221/9
Escherichia urinary tract infectionInfections and infestations0/250/130/221/9
Cardiac failureCardiac disorders0/250/130/221/9
Coronary artery stenosisCardiac disorders0/250/130/221/9
Myocardial infarctionCardiac disorders0/250/130/221/9
Intestinal haemorrhageGastrointestinal disorders0/250/130/221/9
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/130/221/9
Hypovolaemic shockVascular disorders0/250/130/221/9
Endometrial hyperplasiaReproductive system and breast disorders0/180/91/160/6
AgranulocytosisBlood and lymphatic system disorders0/250/131/220/9
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRCP: RavulizumabRCP: PlaceboOLE: Ravulizumab to RavulizumabOLE: Placebo to Ravulizumab
COVID-19Infections and infestations2/253/132/220/9
DiarrhoeaGastrointestinal disorders4/250/130/222/9
AnaemiaBlood and lymphatic system disorders0/252/130/220/9
NeuralgiaNervous system disorders0/252/130/220/9
PruritusSkin and subcutaneous tissue disorders3/251/130/220/9
Diabetic retinopathyEye disorders0/250/130/221/9
Anal erosionGastrointestinal disorders0/250/130/221/9
ConstipationGastrointestinal disorders0/250/130/221/9
Diverticulum intestinalGastrointestinal disorders0/250/130/221/9
Large intestine polypGastrointestinal disorders0/250/130/221/9

Baseline characteristics

Randomized Set, which included all randomized participants grouped by randomized treatment group.

Age, Continuous
Age, Continuous(years)RavulizumabPlaceboTotal
Mean50.7 ± 10.3859.3 ± 9.3153.4 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)RavulizumabPlaceboTotal
Female18927
Male8311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RavulizumabPlaceboTotal
Hispanic or Latino325
Not Hispanic or Latino231033
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RavulizumabPlaceboTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American303
White181028
More than one race000
Unknown or Not Reported101
08

Study locations

111 sites
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    Irvine, California 92617, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Washington D.C., District of Columbia 20037, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Fairway, Kansas 66205, United States
  • Research Site
    Baltimore, Maryland 21205, United States
  • Research Site
    Las Vegas, Nevada 89145, United States
  • Research Site
    Manhasset, New York 11030, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    North Richland Hills, Texas 76180, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Murdoch, WA6150, Australia
  • Research Site
    Belém, 66095-055, Brazil
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Campinas, 13083, Brazil
  • Research Site
    Juiz de Fora, 36010-570, Brazil
  • Research Site
    Natal, 59025-050, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 90480-000, Brazil
  • Research Site
    Salvador, 40150-150, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01308-050, Brazil
  • Research Site
    São Paulo, 05403-010, Brazil
  • Research Site
    Serra, 29160-750, Brazil
  • Research Site
    Vitória, 29050-400, Brazil
  • Research Site
    Lille, 59037, France
  • Research Site
    Lyon, 69437, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Iesi, 60035, Italy
  • Research Site
    Messina, 98124, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Reggio Emilia, 42122, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rome, 00189, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Torrette AN, 60126, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Bunkyō City, 113-8655, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Iruma-Gun, 350-0495, Japan
  • Research Site
    Nagoya, 467-8602, Japan
  • Research Site
    Narita-shi, 286-8520, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Osaka, 565-0871, Japan
  • Research Site
    Sapporo, 060-8648, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Urayasu-shi, 279-0021, Japan
  • Research Site
    Warsaw, 02-637, Poland
  • Research Site
    Daejeon, 35015, South Korea
  • Research Site
    Junggu, 22332, South Korea
  • Research Site
    Seoul, 02447, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 04763, South Korea
  • Research Site
    Seoul, 6591, South Korea
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barakaldo, 48903, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Bilbao (Vizcaya), 48013, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
  • Research Site
    Las Palmas de Gran Canaria, 35020, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Seville, 41010, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46026, Spain

Showing the first 100 of 111 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Oct 2023, 23 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 10, 2021
StartActual
Nov 19, 2021
Primary completionActual
Oct 26, 2023
CompletionActual
May 8, 2024
Results first posted
Dec 6, 2024
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04999020
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Nov 19, 2021
Primary completion
Oct 26, 2023
Completion
May 8, 2024
Results posted
Dec 6, 2024
Last update
Jul 9, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion